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p-S6KPPP2R2C encodes a gamma isoform of the subunit B55 subfamily, which is a regulatory subunit of
Protein phosphatase type 2A (PP2A). Our study shows that PPP2R2C is downregulated in glioma cells
and human brain cancer patient samples. Overexpression of PPP2R2C inhibited cancer cell prolifer-
ation both in vitro and in vivo through the suppression of the activity of S6K in the mTOR pathway.
Moreover, exogenous expression of PPP2R2C promoted the formation of a complex with the PP2A-C
subunit to further enhance the binding of PP2A-C with S6K. Our results suggest that PPP2R2C is a
potential tumor suppressor gene in human brain cancers. This study will provide novel insight into
the development of therapeutic strategies in the treatment of human brain tumors.
Structured summary of protein interactions:
PP2A-C physically interacts with B55 Gamma by anti bait coimmunoprecipitation (View interaction)
B55 Gamma physically interacts with PP2A-C by anti bait coimmunoprecipitation (View interaction)
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction members in these subfamilies [12]. The variable PP2A B subunitsProtein phosphatase type 2A (PP2A) is a serine/threonine phos-
phatase consisting a family of holoenzyme complexes involved cel-
lular behaviors [1]. In general environment, the holoenzyme is a
core dimer, composed of the structural A and catalytic C subunits,
and a regulatory B subunit that associates with a variety of sub-
strates [1,2]. As a serine/threonine phosphatase, PP2A can dephos-
phorylate many signaling enzymes, and inhibition of this
phosphatase can affect cellular activities such as growth, differen-
tiation, and apoptosis [2]. Among the targets of PP2A are proteins
of oncogenic signaling cascades, such as Ras, Raf, MEK, and AKT
[3–6]. This suggests that speciﬁc PP2A holoenzymes play a role
in cellular proliferation and oncogenic transformation [2]. It has
been reported that inhibition of PP2A can cause variety of tumor
type’s growth and metastasis [7–10]. Therefore, understanding
the precise mechanisms how PP2A is involved in the regulation
of these different signaling cascades and its role during oncogenic
transformation requires the identifying speciﬁc regulatory subunit
involved in the progress.
The regulatoryBsubunit canmodulate theactivityof thePP2A,by
targeting a wide range of PP2A substrates [11]. To date, four unre-
lated families of B subunits have identiﬁed: B/B55/PR55/PPP2R2,
B’ /B56/PR61/PPP2R5, B/PR72/PPP2R3, and Striatin with at least 16are targeted by a number of oncogenes, such as Ras and AKT [3,6].
PPP2R2C encodes a gamma isoform of the regulatory subunit B55
subfamily-B55 Gamma. Currently, the precise functions of PPP2R2C
are still under investigating. It has been reported that PPP2R2Chad a
unique expression pattern inmouse brainwhich suggested a role in
learning and memory [13]. They found PPP2R2C was correlated to
intellectual disability (ID). Another study reported that B55 Gamma
wasan inhibitorof c-JunNH2-terminalkinase (JNK)activationbyUV
irradiation. They showed that PR55 gamma bound with c-SRC and
modulated the phosphorylation of serine 12 of c-SRC, a residue
which is required for JNK activation by c-SRC [14].
Although PP2A is a well-studied cancer suppressor protein,
whether PPP2R2C which encodes a B regulatory subunit plays a
role in tumor progression has not been well studied yet. A recent
study by Bluemn et al. demonstrated that loss of PPP2R2C pro-
motes androgen ligand depletion-resistant prostate cancer growth,
which was independent of AR-mediated transcriptional programs
[15], indicating PPP2R2C might be a tumor suppressor gene in
prostate cancers.
In this study, we reported a novel tumor suppression function of
B55 Gammawhich encoded by PPP2R2C in human glioma cells and
brain tumors. PPP2R2C was down regulated in glioma cell lines and
brain tumor patient samples and overexpression of PPP2R2C inhib-
ited the cancer cell proliferation through the suppression of mTOR
pathway. This study will provide novel insight into the tumor sup-
pression function of PPP2R2C and encourage the design and testing
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2. Materials and methods
2.1. Cell lines and patient samples
The human glioma cell lines (U87, U138, NHA, U118 LN18,
U251, T406 and U343) were obtained from ATCC. Cells were grown
adherently in DMEM media supplemented with 10% fetal bovine
serum (FBS; Sigma–Aldrich Chemical Company) and 1% penicil-
lin–streptomycin (GIBCO BRL, Grand Island, NY) and maintained
in a humidiﬁed incubator containing 5% CO2 at 37 C. Cells were
routinely grown in 100-mm plastic tissue culture dishes (Nunc,
Roskilde, Denmark) and harvested with a solution of trypsin–EDTA
while in a logarithmic phase of growth. Cells were maintained in
these culture conditions for all experiments.
All primary Human GBM patient specimens were obtained from
patients undergoing surgery for brain tumor during 2009–2012 at
the Shanghai Renji Hospital Cancer Center and stored in liquid
nitrogen until analysis. Human normal brain whole tissue lysates
(#1, #2 and #3) were purchased from OriGene (CP565621,
CP565723 and CP565732). Human normal brain whole tissue ly-
sates (#4, #5 and #6) were obtained from Shanghai Renji Hospital
Cancer Center. Human primary astrocytes were purchased from
http://www.scinecelloneline.com. All patients provided written in-
formed consent. The study was approved by the Ethics Committee
of the Renji Hospital Cancer Center, Shanghai Jiaotong University
Medical College, Shanghai, China.
2.2. Vectors
Vector containing Myc-DDK-tagged ORF clone of Homo sapiens
protein phosphatase 2, regulatory subunit B, gamma (PPP2R2C),
transcript variant 1 was purchased from Origene (RC224154).
Wild-type S6K and kinase active S6K were purchased from Add-
gene (#26610, #8988: pRK7-HA-S6K1-F5A-E389).
2.3. Antibodies and siRNA
B55Gamma (Sigma SAB1406287); mTOR pathway and sub-
strate antibody sampler kit (Cell signaling #9862 & #9964); b-actin
(Cell signaling #4967); PP2A-A (Cell signaling #2041); PP2A-C (Cell
signaling #2038); siPPP2R2C (EHU059901 Sigma MISSION siRNA
human PPP2R2C).
2.4. Gene expression database analysis
mRNA expression proﬁling of PPP2R2C in human tissues was
analyzed through EMBL-EBI website: http://www.ebi.ac.uk/.
2.5. Immunohistochemistry staining
Immunohistochemistry (IHC) staining of tumor and normal tis-
sue sections was done with an ABC kit using DAB (3,30-Diamino-
benzine) detection. Puriﬁed anti-B55 Gamma antibody (Sigma
SAB1406287) was identiﬁed to stain speciﬁcally on parafﬁn
embedded sections. All normal human brain tissue and GBM pa-
tient samples were from the Biological Resource Centre of Renji
Hospital, Shanghai Jiaotong University Medical College.
2.6. Cell viability assay
Cell viability was measured using CellTiter-Glo™ Luminescent
Cell Viability Assay (Promega). In brief, 1000 cells were seeded in96-well plate and the cell number was measured following manu-
facturer’s instructions.
2.7. Co-immunoprecipitation
For Co-immunoprecipitation (Co-IP), cells were harvested,
washed with PBS, then lysed in IP buffer (50 mM Tris [pH 7.4],
150 mM NaCl, 5 mM EDTA [pH 8.0], 0.5% NP40, 1 mM PMSF, com-
plete Protease Inhibitor Cocktail tablet supplemented with
phosphatase inhibitors [1 mM Na3VO4, 20 mM NaF, 0.1 mM b-
glycerophosphate, 20 mM sodium pyrophosphate]). Lysates were
then cleared by centrifugation (14000 rpm, 10 min) and protein
concentration in supernatants was determined with a BCA protein
assay kit (Pierce, Rockford, IL). Equal amounts of total protein
(2MG) were used for IP as described. Primary antibody and control
IgG were added into lysates for incubation overnight at 4 C cold
room. After 2 h of incubation with agarose G plus beads, beads
were washed and eluted then elutes were subjected to 10% SDS–
PAGE gel electrophoreses.
2.8. Anchorage-independent colony formation assay
For glioma cells foci formation assay, 500 cells were seeded on
10 cm dish with regular cell culture medium. Cells without or with
exogenous PPP2R2C were grown for 2 weeks and the surviving col-
onies were stained with gentian violet after methanol ﬁxation, and
visible colonies (>50 cells) were counted. Colonies from randomly-
selected image areas of three replicate wells were enumerated.
2.9. Western blotting analysis
Cells were lysed with RIPA buffer (50 mM Tris–HCl pH 8,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) sup-
plemented with 5 mM EDTA and HALT Protease Inhibitor Cocktail
(Pierce, Thermo Fisher Scientiﬁc, Rockford, IL). Protein concentra-
tions were determined with BCA Protein Assay kit (Pierce). Unless
stated otherwise, 30 lg of protein lysates were separated in 10%
SDS–PAGE gels and blotted onto nitrocellulose membranes
(Macherey–Nagel, Düren, Germany) and probed with the antibod-
ies listed in the above. Signals were detected using ECL substrate
solution and recorded with Fusion-SL 3500 WL image acquisition
system (Vilber Lourmat, Marne-la-Vallée, France).
2.10. siRNA knockdown of PPP2R2C
siRNA experiments were performed in 24-well plates using
lipofectamine 2000 transfection conditions. Human PPP2R2C-tar-
geting siRNA and negative control siRNA were purchased from Sig-
ma–Aldrich. 24 h after transfection at 400 nM for both negative
control and siPPP2R2C, cell proliferation were assessed by adding
Cell Titer-Glo and measuring luminescence.
2.11. Xenograft tumor growth of glioma cells in nude mice
The female athymice BALB/c nude mice (5–8 week-old) were
housed in the Biological Resource Centre of Renji Hospital, Shang-
hai Jiaotong University Medical College. Mice were implanted sub-
cutaneously in both sides of ﬂank with 3  106 glioma cells
without or with transfection of PPP2R2C, respectively. Tumor pro-
gress was monitored by tumor size measurements at every other
day.
2.12. Statistical data analysis
All data were analyzed using GraphPad Prism 5.04. Quantitative
data are shown as mean ± S.E.M. (standard error of the mean)
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3. Results
3.1. Loss of PPP2R2C expression in human brain tumor cell lines
and patient samples
Since it is well studied that PP2A down regulates multiple sig-
naling in human malignant tumors, we started to seek which reg-
ulatory subunits of PP2A have altered expression proﬁling in
human brain tumor patient samples. From online database re-
search, we found one of the regulatory subunit-PP2A B55 Gamma,
encoded by PPP2R2C, was highly expressed in human brain com-
pared with other tissues (Fig. 1A). Meanwhile, B55 Gamma were
down regulated in brain tumors compared with normal brain tis-
sues (Fig. 1B). Interestingly, the expression levels of B55 Gamma
were correlated with brain tumor malignancy stages (Fig. 1B), indi-
cating there was correlation between the expression of PPP2R2C
and human brain tumor progress. We next investigated the expres-
sion of B55 Gamma in multiple human glioma cell lines and found
that B55 Gamma were consistently down regulated or silenced in
all examined human glioma cell lines, but not in the normal human
Astrocytes (Fig. 1C). Similar results came out when we compared
with different sections of human brain, we found primary normal
human brain cells highly expressed B55 Gamma (Fig. 1C). More-
over, our results showed the expression of B55 Gamma was signif-
icantly correlated with the occurrence of human brain tumors byFig. 1. PPP2R2C is down regulated in human glioma cells and brain tumors. (A) PPP2R
PPP2R2C in human normal tissues shows PPP2R2C is higher expressed in brain tissue an
stating shows the expression of PPP2R2C in brain tumor patient samples compared wi
glioma cells. Seven human glioma cells were collected and the human normal brain tiss
primary brain cells compared with human glioma cells. (D) Expression of B55Gamma inwestern blotting (Fig. 1D). In summary, our data showed PPP2R2C
were deregulated in brain tumors, but highly expressed in normal
brain tissue, indicating this gene had brain tumor suppression
function.
3.2. PPP2R2C re-expression results in decreased proliferation rates
in glioma cells
Loss of PPP2R2C expression in brain tumors suggested that it
might inhibit cancer cells growth. To test this hypothesis, we stably
transfected pCMV6-Myc-DDK-PPP2R2C into three glioma cell
lines: U87, U138 and U118 (Fig. 2A). By exogenous restored
expression of PPP2R2C, glioma cells resulted in a signiﬁcant prolif-
eration inhibition under regular cell culture conditions (Fig. 2B), as
well as increased colony formation inhibition in fourteen days
(Fig. 2C). All these functional analysis supported our hypothesis
that PPP2R2C was a potential tumor suppressor gene.
3.3. PPP2R2C inhibits mTOR pathway through de-phosphorylation
of S6K
We next explored the possible mechanisms for the PPP2R2C
mediated cancer cells growth inhibition. Since mTOR plays a key
role in cell growth and homeostasis and may be abnormally regu-
lated in tumors [16,17], the plausible connection between PPP2R2C
and mTOR signaling prompted us to investigate the possibility
that the PPP2R2C expression status may affect the activities of
mTOR downstream targets: p70S6K and 4EBP1. Interestingly,2C is differentially expressed in human organism parts. Transcription proﬁling of
d spinal cord. (Data shown for array design: A-AFFY-10). (B) Immunohistochemistry
th normal brain tissue. (C) Expression of PPP2R2C encoded protein B55 Gamma in
ue was positive control (left). Expression of B55 Gamma in multiple normal human
GBM patients compared with normal brain tissue.
Fig. 2. Overexpression of PPP2R2C in human glioma cell lines inhibits cells growth. (A) Overexpression of PPP2R2C in U87, U138 and U118 glioma cells. (B) Cell proliferation
rates are inhibited by overexpression of PPP2R2C. (C) Overexpression of PPP2R2C suppresses colony formation of glioma cells.
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the phosphorylation of S6K, but not the phosphorylation of 4EBP1
(Fig. 3). In addition, the phosphorylation of mTOR and phosphory-
lation of AKT which is the upstream regulator of mTOR did not
change neither, suggesting S6K might be a potential target of
PPP2R2C. To further strengthen our results, we transfected wild-
type (S6KWT) and kinase active mutant (S6K KA) of S6K into con-
trol and B55 Gamma overexpression glioma cells, followed by the
detection of cell proliferation rates. As we showed in Fig. 3B,
S6KWT only slightly abated the inhibitory effect on the prolifera-
tion in glioma cells overexpressing B55 Gamma (U87, U138 and
U118), however, transfection of S6K KA signiﬁcantly reversed the
inhibitory effects on cell proliferation in B55 Gamma overexpres-
sion cells. These data indicated B55 Gamma inhibited glioma cell
proliferation through de-phosphorylation of S6K. To further sup-
port our hypothesis, we treated U87V, U87 B55 Gamma, U138V,
U138 B55 Gamma, U118V and U118 B55 Gamma cells with Rapa-
mycin which is well studied mTOR pathway inhibitor targeting on
the inhibition of S6K activities. Fig. 3C showed B55 Gamma over-
expressing cells were insensitive to Rapamycin treatments com-
pared with control cells, that because the basal level of
phosphor-S6K is deceased by B55 Gamma, resulting in the loss of
target of Rapamycin. To further verify our ﬁnding, we transfected
speciﬁc siRNA to knockdown PPP2R2C expression in NHA cells
which highly express PPP2R2C. Fig. 4A showed partial recovery
of phosphorylation of S6K by knocking down of PPP2R2C, support-
ing our previous data that PPP2R2C dephosphorylated S6K. To fur-
ther verify our results, knocking down of PPP2R2C rehabilitated
NHA cells growth (Fig. 4B). Thus, all these data supported our con-
clusions that B55 Gamma targeted on phosphorylation of S6K
which was the mechanism for the inhibition of cells proliferation.3.4. B55 Gamma subunit forms complex with PP2A-C subunits and
enhances the binding of PP2A-C with S6K
To further exam mechanisms of the PPP2R2C mediated dephos-
phorylation of S6K, we designed experiments to check whether the
PPP2R2C encoded B regulatory subunit had direct interaction with
S6K. Immunoprecipitation results showed that exogenous B55
Gamma did bind with other subunits of PP2A to form PP2A com-
plex in U87 cells (data not shown), while the total protein levels
of PP2A-A and C subunits did not change by overexpression of
B55 Gamma (data not shown).
It has been reported PP2A-B subunit has multiple substrates
which play important roles in the regulation of cell proliferation,
energy metabolism [15]. We next investigated whether S6K is a di-
rect target of B55 Gamma. Out of our expectations, however, B55
Gamma did not interact with S6K (Fig. 3D left & middle) in U87
B55 Gamma and other glioma cell lines (data not shown). But it
was still interesting that although B55 Gamma did not bind with
S6K, overexpression of B55 Gamma enhanced the binding of
PP2A catalytic subunit with S6K (Fig. 3D middle & right). These
results provided mechanisms to support our previous data that
overexpression of B55 Gamma in glioma cells inhibited the
phosphorylation of S6K.
3.5. Overexpression of PPP2R2C inhibits xenograft tumor growth
To verify the in vitro results in vivo, we studied the effects of
over expression of PPP2R2C on the xenograft tumor growth in
nude mice. We injected human glioma cells with or without over-
expression of PPP2R2C into nude mice. After three weeks, mice
with exogenous PPP2R2C attenuated the tumor sizes, indicating
Fig. 3. PPP2R2C inhibits mTOR pathway through de phosphorylation of S6K but not 4EBP1. (A) Overexpression of PPP2R2C in glioma cells decreases phosphorylation of S6K,
but phosphorylation of AKT and 4EBP1 have no signiﬁcant change. (B) Cell proliferation rates at 24 h and 48 h after cells were transfected with wild-type S6K and Kinase
active S6K in B55 Gamma overexpression glioma cells compared with control cells. (C) Cell viability of the B55 Gamma overexpression glioma cells and control cells after the
treatments of Rapamycin. (D) Exogenous B55 Gamma does not interact with S6K but enhance the binding of PP2A-C with S6K.
Fig. 4. Knocking down PPP2R2C in NHA cells. (A) Knocking down PPP2R2C in NHA cells recovers phosphorylation of S6K and mTOR activity. (B) Knocking down PPP2R2C in
NHA cells promotes cell proliferation.
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with the injection of glioma cells without PPP2R2C expression
(Fig. 5). Collectively, these results obtained from both in vitro
and in vivo experiments established that the PPP2R2C had tumor
suppressor potential and might lead to a therapeutic aspect for hu-
man glioma cancer patients.4. Discussions
It has been reported multiple evidence suggested that the ser-
ine/threonine protein phosphatase 2A (PP2A) might be a tumor
suppressor protein which acts in a wide variety of signaling path-
ways in cancer cells. The ﬁrst hint of PP2A’s tumor suppressing
Fig. 5. Overxpression of PPP2R2C in nude mice inhibits Xenograft Tumor Growth
Nude mice were injected human glioma cells with or without overexpression of
PPP2R2C. After two weeks, three weeks and four weeks mice were sacriﬁced and
tumor sized were measured.
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not speciﬁc inhibitor of PP2A, was shown to potently promote tu-
mors in a mouse model of carcinogenesis [18]. The second clue
came with the discovery that PP2A was the target of the small tu-
mor antigen (small-t) of two transforming DNA viruses, SV40 and
polyoma virus [19]. Because PP2A directly regulates the activity
of more than 50 kinases and other known proto-oncogenes, this
will likely require extensive experiments with an emphasis on
identiﬁcation of substrates in response to the deregulated survival
and growth of human brain cancers.
PPP2R2C encodes a gamma isoform of the regulatory subunit
B55 subfamily. Currently, very few paper reports the functions of
PPP2R2C in cancer. It has been reported the subcellular localization
of PPP2R2C is tissue speciﬁc: in osteosarcoma cells, investigators
detected perinuclear expression of PPP2R2C [20], other published
data showed PPP2R2C had distinct nuclear localization in prostatic
tissue [15]. Meanwhile, PPP2R2C is localized in nuclear in the Jur-
kat cell line and rat epidermis [21,22].
In this project, bioinformatics research reveled PPP2R2C was
highly expressed in human brain and PPP2R2C was downregulated
in human brain tumor compared with normal brain tissue, which
indicated this gene had a potential tumor suppression function.
Our data showed that B55 Gamma was down regulated in glioma
cells and overexpression of B55 Gamma inhibited the cancer cells
proliferation through the suppression of mTOR pathway. The pro-
motion of the growth of human normal astrocytes via decreased
PPP2R2C expression reveals an important therapeutic development
strategy in clinical patient treatments. We further investigated the
interaction between PP2A catalytic subunit and S6K which might
be the potential mechanism accounting for the B55 Gamma medi-
ated inhibition of mTOR pathway. However, detailed mechanisms
will need further studies. The mechanism that enhances the bind-
ing of S6K and PP2A-A is still unclear, does S6K bind with PP2A-A
directly or indirectly? Our next project will focus on the mecha-
nisms how B55 Gamma de-phosphorylates S6K. Currently, we al-
ready identiﬁed more than one putative binding partners of B55
Gamma by proteomics approaches and nowwe are under the func-
tional studies of those proteins. It is very interesting that when cells
express high levels of B55 Gamma, those cells become insensitive to
Rapamycin treatment. Since Rapamycin is a well-accepted anti-tu-
mor drug, our data might provide a novel perspective on the study
of anti-tumor drug resistance in brain tumor patients.
In general, we provided evidence that overexpression of the
regulatory PP2A subunit, PPP2R2C, inhibited glioma cells growth.
Our study provided a novel functional study on one of the regula-
tory subunit of PP2A, B55 Gamma, revealing a potential tumor
suppressor protein, which will be a therapeutic target for the
treatment of human brain tumor patient.Author contributions
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